Large-scale clinical trials and other research are “urgently required” to determine the best ways to manage the growing number of infections with nontuberculous mycobacteria — known as NTM — among children with cystic fibrosis (CF). That’s the argument made by a team of scientists in the U.K., in the…

Inhaled nitric oxide (NO) was shown to be an effective antibacterial agent against Mycobacterium abscessus infection in preclinical studies, as well as in a pilot clinical trial, according to AIT Therapeutics. The company discussed the latest data on its NO product in two poster presentations during the 3rd Annual…

AIT Therapeutics will present new research on the use of inhaled nitric oxide in the treatment of Mycobacterium abscessus lung infections at an upcoming conference, the company recently announced. Data from lab studies and a compassionate use study will be presented at the 3rd Annual World Bronchiectasis Conference July…

New data suggest that inhalation of nitric oxide (NO) may improve lung function and alleviate the burden of serious lung infections, such as Mycobacterium abscessus complex (MABSC) and Pseudomonas aeruginosa, two serious pathogens affecting cystic fibrosis (CF) patients. Results from the Advanced Inhalation Therapies (AIT) pilot study were shared recently at the…

AIT Therapeutics’ nitric oxide mist led to a 65 percent reduction in cystic fibrosis patients’ airway bacteria and an improvement in their exercise capability 60 days after treatment, a Phase 2 clinical trial shows. The bacteria that the nitric oxide countered was the Mycobacterium abscessus complex. The exercise-capability yardstick researchers…

AIT Therapeutics’ inhaled nitric oxide formulation improved the breathing and physical functioning of cystic fibrosis patients with a lung infection, a Phase 2 clinical trial shows. The preliminary results applied to the formulation’s use against nontuberculous mycobacteria, which are collectively known as the mycobacterium abscessus complex. AIT said the NO-NTM…

A nitric oxide therapy that AIT Therapeutics‘ is developing to treat respiratory diseases eradicated a drug-resistant bacteria in one cystic fibrosis patient and reduced it in another, according to a Phase 2 clinical trial. The patients received the treatment under the Food and Drug Administration’s compassionate use program, which allows…

AIT Therapeutics has administered its first doses of nitric oxide in a Phase 2 clinical trial of the compound’s ability to kill the drug-resistant bacteria often found in cystic fibrosis patients. The study’s overarching goal is to see whether AIT’s nitric oxide formulation can eliminate nontuberculous mycobacteria, or NTM, in patients…

Multi-drug-resistant nontuberculous mycobacteria (NTM) can be found in the gastric juice and tubes that are used to feed some cystic fibrosis (CF) patients, research shows. Tube feeding, known as gastrostomy, involves surgeons inserting a tube through the abdominal wall and into the stomach. Gastrostomy can also be used to drain…